Advancements in Thyroid Cancer Management

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Head and Neck Oncology".

Deadline for manuscript submissions: closed (30 November 2025) | Viewed by 2244

Special Issue Editor


E-Mail Website
Guest Editor
Unit of Endocrine Surgery, Department of Surgical, Medical, Molecular Pathology and Critical Area, Pisa University Hospital, 56124 Pisa, Italy
Interests: thyroid cancer; active surveillance; targeted therapy; lymph node dissection; surgical treatment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Thyroid cancer has witnessed a notable increase in incidence over recent decades, prompting a continuous evolution in diagnostic modalities and therapeutic strategies. While surgical interventions have long been the cornerstone of thyroid cancer management, the landscape of treatment has expanded significantly to encompass medical therapies, radioiodine ablation, and targeted therapies. This Special Issue aims to provide a comprehensive overview of the latest advancements across the spectrum of thyroid cancer treatment. By bringing together the expertise of leading researchers and clinicians in the field, this Special Issue will serve as a valuable resource for anyone involved in the care of patients with thyroid cancer.

We invite original research articles, review articles, and meta-analyses that address the following key areas:

  • Surgical advancements: The evolution of surgical techniques, driven by technological advancements and a deeper understanding of the disease, has significantly improved patient outcomes. Contributions exploring minimally invasive and remote-access surgery, nodal management, and the management of advanced disease are encouraged.
  • Medical therapies: the role of medical therapies, including tyrosine kinase inhibitors and other targeted agents, is of great interest in the management of thyroid cancer, both as adjuvant and first-line treatments.
  • Emerging technologies: The field of thyroid cancer treatment is continually evolving. Contributions exploring emerging technologies, such as US-guided ablation, and their potential applications in thyroid cancer are welcome.
  • Quality of life and patient-reported outcomes: The impact of treatment on patients' quality of life is a critical consideration. Studies investigating the long-term functional outcomes, cosmetic results, and patient satisfaction following thyroid cancer treatment are encouraged. Moreover, we reserve special attention to active surveillance.

Dr. Leonardo Rossi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thyroid cancer
  • active surveillance
  • targeted therapy
  • lymph node dissection
  • thyroid nodule ablation
  • remote-access thyroidectomy
  • minimally invasive thyroidectomy
  • medullary thyroid carcinoma
  • anaplastic thyroid carcinoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Research

5 pages, 455 KB  
Editorial
New Trends in Thyroid Malignancy: Minimally Invasive Thermal Ablation Percutaneous Techniques for T1 Papillary Thyroid Carcinomas
by Pierre Yves Marcy
Curr. Oncol. 2025, 32(8), 442; https://doi.org/10.3390/curroncol32080442 - 7 Aug 2025
Viewed by 1229
Abstract
During the late 1990s, thyroid nodule management strongly improved with the development of high-frequency ultrasound (HFUS) and US-guided percutaneous procedures [...] Full article
(This article belongs to the Special Issue Advancements in Thyroid Cancer Management)
Show Figures

Figure 1

Research

Jump to: Editorial

16 pages, 4545 KB  
Article
Cytotoxic Effects of Sorafenib, Lapatinib, and Bevacizumab, Alone and in Combination, on Medullary Thyroid Carcinoma Cells
by Gülşah Altun and Özlem Yönem
Curr. Oncol. 2025, 32(11), 607; https://doi.org/10.3390/curroncol32110607 - 31 Oct 2025
Viewed by 345
Abstract
Background: Medullary thyroid carcinoma is a rare neuroendocrine tumor with limited therapeutic options, as current kinase inhibitors are often associated with significant toxicity and drug resistance. This study aimed to explore novel treatment strategies by testing targeted agents alone and in combination. Methods: [...] Read more.
Background: Medullary thyroid carcinoma is a rare neuroendocrine tumor with limited therapeutic options, as current kinase inhibitors are often associated with significant toxicity and drug resistance. This study aimed to explore novel treatment strategies by testing targeted agents alone and in combination. Methods: Human medullary thyroid carcinoma TT cells with RET mutations were treated with Sorafenib, Lapatinib, and Bevacizumab. Cell proliferation was monitored in real time using the xCELLigence system, and apoptosis was assessed by flow cytometry. Results: Sorafenib and Lapatinib each showed strong, dose-dependent cytotoxic effects, with Lapatinib demonstrating the greatest potency. Bevacizumab alone exhibited minimal cytotoxic activity, but when combined with Sorafenib or Lapatinib it significantly enhanced their effects, even at concentrations that were only partially effective individually. The Lapatinib–Bevacizumab combination produced the most potent inhibition of cell viability, comparable to high-dose monotherapy. Conclusions: These findings suggest that combining kinase inhibitors with Bevacizumab may enhance antitumor activity, allow the use of lower drug doses, and overcome resistance, representing a promising therapeutic strategy for medullary thyroid carcinoma that warrants further investigation in clinical settings. Full article
(This article belongs to the Special Issue Advancements in Thyroid Cancer Management)
Show Figures

Graphical abstract

Back to TopTop